Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

NCT04436822 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Interventions

  • DEVICE Continuous Glucose Monitoring

Study Locations (18)

California

  • AMCR Institute — Escondido
  • Sansum Diabetes Research Institute — Santa Barbara
  • SoCal Diabetes — Torrance
  • Diablo Clinical Research, Inc. — Walnut Creek

Colorado

  • Barbara Davis Center for Childhood Diabetes — Aurora
  • Barbara Davis Center for Diabetes — Aurora

Shanghai Municipality

  • Shanghai Sixth People's Hospital — Shanghai
  • Children's Hospital of Fudan University — Shanghai

Florida

  • University of South Florida — Tampa

Georgia

  • Atlanta Diabetes Associates — Atlanta

Idaho

  • Rocky Mountain Diabetes and Osteoporosis Center — Idaho Falls

Tennessee

  • AM Diabetes and Endocrinology Center — Bartlett

Texas

  • Texas Diabetes & Endocrinology — Austin

Trial Details

FieldValue
Enrollment Target 317 participants
Start Date 2020-07-15
Est. Completion 2022-04-12
Phase NA

Sponsor

Medtronic Diabetes

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04436822

The ClinicalTrials.gov registry entry for NCT04436822 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Diabetes, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention — of which Continuous Glucose Monitoring is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04436822 reports 18 study locations spanning 13 distinct geographic areas — top geographies include California, Colorado, Shanghai Municipality. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04436822 about?

NCT04436822 is a clinical study titled "Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics". The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).

What is the current status of trial NCT04436822?

This trial is currently completed. It is a NA study. The enrollment target is 317 participants. The study started on 2020-07-15. Estimated completion is 2022-04-12.

What conditions does trial NCT04436822 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04436822?

The interventions under investigation include: Continuous Glucose Monitoring (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04436822?

This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04436822 being conducted?

This trial has 18 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial